Literature DB >> 8139580

More efficient peptide binding to MHC class II molecules during cathepsin B digestion of Ii than after Ii release.

M Daibata1, M Xu, R E Humphreys, V E Reyes.   

Abstract

The binding of a T cell-presented peptide to MHC class II alpha,beta chains occurs as a concurrent process with the release of the associated invariant chain (Ii) by cathepsin B. Ii was digested by cathepsin B from solubilized, MHC class II alpha,beta,Ii complexes in the presence of N-hydroxysuccinimidyl-4-azidobenzoate-conjugated, 125I-labeled, influenza virus matrix (18-29) peptide. The peptide was crosslinked where it became bound. This HLA-DR1-restricted peptide bound about three times more efficiently to class II alpha,beta chains of DR1-positive B cells when present during cathepsin B digestion of Ii than when added afterward, also at pH 5.0. Binding was competed by similarly DR-restricted peptides. Cathepsin D cleaved Ii but did not enhance peptide binding. However, a trace level of cathepsin D, added to the assay for peptide binding in the presence of cathepsin B, further enhanced peptide binding about three times. These experiments support an hypothesis for the staged release of Ii fragments by cathepsin D and cathepsin B, catalyzing at one point the insertion of a peptide into the antigen binding site formed by class II alpha and beta chains.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8139580     DOI: 10.1016/0161-5890(94)90122-8

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  3 in total

Review 1.  Hsp70--a multi-gene, multi-structure, multi-function family with potential clinical applications.

Authors:  U Feige; B S Polla
Journal:  Experientia       Date:  1994-11-30

2.  Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism.

Authors:  J A Villadangos; R J Riese; C Peters; H A Chapman; H L Ploegh
Journal:  J Exp Med       Date:  1997-08-18       Impact factor: 14.307

3.  Interferon-γ treatment in vitro elicits some of the changes in cathepsin S and antigen presentation characteristic of lacrimal glands and corneas from the NOD mouse model of Sjögren's Syndrome.

Authors:  Zhen Meng; Wannita Klinngam; Maria C Edman; Sarah F Hamm-Alvarez
Journal:  PLoS One       Date:  2017-09-13       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.